ImmunOs Therapeutics
ImmunOs’ approach is based on the identification of specific human leukocyte antigen (HLA) molecules that hyper-activate the immune system of patients with severe autoimmune disorders. The company has utilized this discovery to develop an HLA-based technology platform to generate a novel class of biologic therapeutics for the treatment of cancer and autoimmune disease.
Date, time and room information
May 5, 15:15 - 15:30, room Montreal
Category
Clinical stage development company
Title of the presentation
Inhibition of multiple innate immune-checkpoint receptors by IOS-1002 demonstrates synergistic activity with pembrolizumab in patients with advanced stage cancer
Speaker information
| Name | Position | Institution |
|---|---|---|
| Renner | CMO | Immunostherapeutics |
Host and event manager:
Logistics and marketing partner:
